Gemcitabine Plus Cisplatin vs Gemcitabine Plus Carboplatin in Metastatic Triple-Negative Breast

19 Mar 20265 min read0 viewsJournal Feed

GIST (Key Takeaways)

Platinum-based regimens play an essential role in triple-negative breast cancer (TNBC) treatment, with the CBCSG006 study establishing the position of gemcitabine plus cisplatin (GP) as a first-line treatment of metastatic TNBC.
Our study aims to further improve the efficacy of the first-line platinum-based chemotherapy for metastatic TNBC by optimizing the selection of platinum.

Clinical Editorial

ESMO Open published a clinical update in Oncology on 19 Mar 2026.

The item focuses on A phase II randomized trial of gemcitabine plus cisplatin (GP) versus gemcitabine plus carboplatin (GC) as the first-line treatment of patients with metastatic triple-negative breast cancer☆.

Review the original article for the full source wording and details.